WASHINGTON—Magnesium-containing antacids may increase the risk for hip fracture in patients with chronic kidney disease (CKD) and those on dialysis,according to new study findings presented at the American Society of Nephrology’s Kidney Week 2019 meeting.
Using the Taiwan National Health Insurance Research Database, investigators identified 10,361 patients with kidney disease who suffered a hip fracture (mean age 69.7 years; 54.7% non-dialysis CKD) and stratified them by their use of magnesium, aluminum, and calcium antacids.
Users of magnesium-containing antacids had significant 15% greater odds of hip fracture than nonusers of antacids, regardless of whether they had non-dialysis CKD or received maintenance dialysis, or were male or female, David Chih-Yu Yang, MD, of Taipei Veterans General Hospital in Taiwan, and colleagues reported.
The authors found a dose-dependent relationship between magnesium-containing antacids and hip fracture risk. Compared with no antacid use, magnesium-containing antacid dosages in the first, second, third, and fourth quartiles were associated with significant 11%, 23%, 33%, and 20% increased odds of hip fracture, respectively. The investigators found no relationship between hip fracture risk and use of aluminum- or calcium-containing antacids. The team adjusted for steroid use.
The authors concluded that their findings indicate a strong link between magnesium-containing antacid exposure and incident hip fracture risk in both non-dialysis CKD and dialysis patients, suggesting that magnesium-containing antacids should be prescribed cautiously in the CKD population.
Yang DCY, Chen YT, Lee OKS, Tarng, DC. Magnesium exposure increases fracture risks in patients with CKD. Presented at the American Society of Nephrology’s Kidney Week 2019 meeting held November 5-10, 2019 in Washington DC. Poster TH-PO569.